Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dr Reddys Laboratories ADR repsg 1 Ord Shs RDY

Healthcare
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The... see more

Recent & Breaking News (NYSE:RDY)

Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market

Business Wire December 9, 2021

Prestige BioPharma and Dr. Reddy's announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia

Business Wire December 8, 2021

Dr. Reddy's Laboratories Announces the Launch of Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial in the U.S. Market

Business Wire October 29, 2021

Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)

Business Wire October 19, 2021

Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market

Business Wire October 15, 2021

Beroni Group Received Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAO

GlobeNewswire September 9, 2021

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

PR Newswire September 7, 2021

Dr. Reddy's Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)

Business Wire September 4, 2021

Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market

Business Wire September 2, 2021

Dr. Reddy's Laboratories Announces the Launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP in the U.S. Market

Business Wire August 31, 2021

Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO

GlobeNewswire August 18, 2021

Dr. Reddy's Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg/mL

Business Wire August 4, 2021

Dr. Reddy's Announces the Re-Launch of Over-the-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve® in the U.S. Market

Business Wire August 3, 2021

Dr. Reddy's Laboratories Announces Filing of Annual Report on Form 20-F

Business Wire June 30, 2021

Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy's Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea

GlobeNewswire June 30, 2021

Dr. Reddy's Laboratories Announces the Launch of Icosapent Ethyl Capsules, 1 Gram in the U.S. Market

Business Wire June 22, 2021

Global Response Aid Reports Midyear Sales Results for COVID Drug

PR Newswire June 3, 2021

Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market

Business Wire May 12, 2021

Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market

Business Wire April 29, 2021

Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India

Business Wire April 13, 2021